358
Views
56
CrossRef citations to date
0
Altmetric
Review

Role of Factor XII in hemostasis and thrombosis: clinical implications

&
Pages 733-741 | Published online: 10 Jan 2014

References

  • Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet349(9061), 1269–1276 (1997).
  • Rosenberg RD, Aird WC. Vascular-bed – specific hemostasis and hypercoagulable states. N. Engl. J. Med.340(20), 1555–1564 (1999).
  • Furie B, Furie B. Molecular and cellular biology of blood coagulation. N. Engl. J. Med.326, 800–806 (1992).
  • Ruggeri ZM. Platelets in atherothrombosis. Nat. Med.8(11), 1227–1234 (2002).
  • Furie B, Furie BC. Thrombus formation in vivo. J. Clin. Invest.115(12), 3355–3362 (2005).
  • Walsh PN. Platelet coagulation–protein interactions. Semin. Thromb. Hemost.30(4), 461–471 (2004).
  • Johne J, Blume C, Benz PM et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol. Chem.387(2), 173–178 (2006).
  • Colman RW, Clowes AW, George J, Goldhaber SZ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins, PA, USA (2006).
  • Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest119(1 Suppl.), 108S–121S (2001).
  • Weitz JI, Bates SM. New anticoagulants. J. Thromb. Haemost.3(8), 1843–1853 (2005).
  • Schulman S, Ogren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb. Haemost.96(3), 258–266 (2006).
  • Colman RW. Are hemostasis and thrombosis two sides of the same coin? J. Exp. Med.203(3), 493–495 (2006).
  • Kleinschnitz C, Stoll G, Bendszus M et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med.203(3), 513–518 (2006).
  • Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature202, 498–499 (1964).
  • Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science145, 1310–1312 (1964).
  • Furie B, Furie B. The molecular basis of blood coagulation. Cell53, 505–518 (1988).
  • Lane DA, Philippou H, Huntington JA, Directing thrombin. Blood106, 2605–2612 (2005).
  • Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood90(7), 2615–2625 (1997).
  • Rosen ED, Chan JC, Idusogie E et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature390(6657), 290–294 (1997).
  • Bugge TH, Xiao Q, Kombrinck KW et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl Acad. Sci. USA.93(13), 6258–6263 (1996).
  • Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol.24(6), 1015–1022 (2004).
  • Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int. J. Hematol.79(2), 103–108 (2004).
  • Falati S, Liu Q, Gross P et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med.197(11), 1585–1598 (2003).
  • Chou J, Mackman N, Merrill-Skoloff G et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood104(10), 3190–3197 (2004).
  • Day SM, Reeve JL, Pedersen B et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood105(1), 192–198 (2005).
  • Butenas S, Mann KG. Active tissue factor in blood? Nat. Med.10(11), 1155–1156 (2004).
  • Colman RW. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive and Antiangiogenic Activities. Colman RW, Mader VJ, Clowes AW, George J (Eds). Lippincott Williams & Wilkins, PA, USA (2001).
  • Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem.275(43), 33688–33696 (2000).
  • Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J. Immunol.175(5), 3377–3385 (2005).
  • Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem.268(13), 9496–9503 (1993).
  • Schmaier AH. The kallikrein–kinin and the renin–angiotensin systems have a multilayered interaction. Am. J. Physiol.285(1), R1–R13 (2003).
  • Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N. Engl. J. Med.347(8), 621–622 (2002).
  • Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet356(9225), 213–217 (2000).
  • Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am. J. Hum. Genet.79(6), 1098–1104 (2006).
  • Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun.343(4), 1286–1289 (2006).
  • Levi M, Hack C, de Boer J et al. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J. Clin. Invest.88, 1155–1160 (1991).
  • Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med.153(3), 665–676 (1981).
  • Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost.5, 1106–1112 (2007).
  • Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arterioscler. Thromb. Vasc. Biol.25(12), 2463–2469 (2005).
  • Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays25(12), 1220–1228 (2003).
  • Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J. Exp. Med.138(6), 1564–1583 (1973).
  • Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv. Immunol.33, 241–306 (1982).
  • Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood63(6), 1453–1459 (1984).
  • Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. Acidocalcisomes – conserved from bacteria to man. Nat. Rev. Microbiol.3(3), 251–261 (2005).
  • Smith SA, Mutch NJ, Baskar D et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc. Natl Acad. Sci. USA.103(4), 903–908 (2006).
  • Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl Acad. Sci. USA104, 6388–6393 (2007)
  • Herwald H, Morgelin M, Olsen A et al. Activation of the contact-phase system on bacterial surfaces – a clue to serious complications in infectious diseases. Nat. Med.4(3), 298–302 (1998).
  • Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood90(10), 3819–3843 (1997).
  • Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J. Biol. Chem.262(21), 10140–10145 (1987).
  • Clarke BJ, Cote HC, Cool DE et al. Mapping of a putative surface-binding site of human coagulation factor XII. J. Biol. Chem.264(19), 11497–11502 (1989).
  • Citarella F, Ravon DM, Pascucci B et al. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur. J. Biochem.238(1), 240–249 (1996).
  • Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood86(11), 4134–4143 (1995).
  • Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. Clin. Invest.34(4), 602–613 (1955).
  • Ratnoff OD. The George M. Kober lecture. The legacy of John Hageman: new dividends. Trans. Assoc. Am. Physicians98, CLI–CLXI (1985).
  • Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis1, 259 (1987b).
  • Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol.137(3), 459–464 (2004).
  • Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb. Haemost.68(3), 285–290 (1992).
  • Korte W, Otremba H, Lutz S et al. Childhood stroke at three years of age with transient protein C deficiency, familial antiphospholipid antibodies and F. XII deficiency – a family study. Neuropediatrics25(6), 290–294 (1994).
  • Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis17(2), 139–143 (2004).
  • Zeerleder S, Schloesser M, Redondo M et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency – a study on 73 subjects from 14 Swiss families. Thromb. Haemost.82(4), 1240–1246 (1999).
  • Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia study. Br. J. Haematol.87(2), 422–424 (1994).
  • Saito H. Contact factors in health and disease. Semin. Thromb. Hemost.13(1), 36–49 (1987).
  • Lammle B, Wuillemin W, Huber I et al. Thrombo-embolism and bleeding tendency in congenital factor XII deficiency: a study of 74 subjects from 14 Swiss families. Thromb. Haemost.65, 117–121 (1991).
  • Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol.23(1), 17–25 (2003).
  • Endler G, Marsik C, Jilma B et al. Evidence of a U-shaped association between FXII activity and overall survival. J. Thromb. Haemost. DOI:10.1111/j.1538-7836.2007.02530.x (2007) (Epub ahead of print).
  • Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood108(13), 4045–4051 (2006).
  • von dem Borne P, Meijers J, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood86, 3035–3042 (1995).
  • Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) – how does thrombin regulate fibrinolysis? Ann. Med.38(6), 378–388 (2006).
  • Meijers J, Tekelenburg W, Bouma B, Bertina R, Rosendaal F. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med.342, 696–701 (2000).
  • La Follette L, Gordon EM, Mazur CA, Ratnoff OD, Yamashita TS. Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction. J. Lab. Clin. Med.110(3), 318–321 (1987).
  • Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein–kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation91(10), 2520–2527 (1995).
  • Citarella F, Felici A, Brouwer M et al. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood90(4), 1501–1507 (1997).
  • Gordon EM, Donaldson VH, Saito H, Su E, Ratnoff OD. Reduced titers of Hageman factor (factor XII) in Orientals. Ann. Intern. Med.95(6), 697–700 (1981).
  • Kanaji T, Okamura T, Osaki K et al. A common genetic polymorphism (46 C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood91(6), 2010–2014 (1998).
  • Kaplan AP. Intrinsic coagulation, thrombosis, and bleeding. Blood87(5), 2090 (1996).
  • Cooper JA, Miller GJ, Bauer KA et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation102(23), 2816–2822 (2000).
  • Zito F, Drummond F, Bujac SR et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation102(17), 2058–2062 (2000).
  • Colhoun HM, Zito F, Norman Chan N et al. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis163(2), 363–369 (2002).
  • Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am. Heart J.147(2), 260–266 (2004).
  • Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat. Biotechnol.18(3), 289–295 (2000).
  • Ponitz V, Pritchard D, Grundt H, Nilsen DW. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J. Thromb. Thrombolysis22(3), 199–203 (2006).
  • Ponitz V, Pritchard D, Grundt H, Mehus MB, Nilsen DW. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI). J. Thromb. Thrombolysis DOI:10.1007/s11239-007-0041-9 (2007) (Epub ahead of print).
  • Pauer HU, Renne T, Hemmerlein B et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost.92(3), 503–508 (2004).
  • Mann KG. Thrombin formation. Chest124(3 Suppl.), 4S–10S (2003).
  • Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl Acad. Sci. USA74(12), 5260–5264 (1977).
  • Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science253(5022), 909–912 (1991).
  • Renne T, Pozgajova M, Gruner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med.202(2), 271–281 (2005).
  • Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb. Haemost.87(4), 774–776 (2002).
  • Wang X, Cheng Q, Xu L et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J. Thromb. Haemost.3(4), 695–702 (2005).
  • Wang X, Smith PL, Hsu MY et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J. Thromb. Haemost.4(9), 1982–1988 (2006).
  • Tans G, Janssen-Claessen T, Rosing J, Griffin JH. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur. J. Biochem.164(3), 637–642 (1987).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.